A completely novel biologic for the treatment of rheumatoid arthritis is poised to enter the US market.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Garber, K. First-in-class biologic to enter rheumatoid arthritis fray. Nat Biotechnol 23, 1323–1324 (2005). https://doi.org/10.1038/nbt1105-1323
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1105-1323
This article is cited by
-
Cimzia's setback paves way for other TNF inhibitors in Crohn's disease
Nature Biotechnology (2007)
-
London's disastrous drug trial has serious side effects for research
Nature (2006)